The deal could be worth more than $1 billion, if all genetic targets identified lead to approved therapeutics.
Investigators at CHOP and UPenn found that lower cell counts could still be associated with poor outcomes if the cells were ...
The NICE committee concluded that it needed additional data on various survival endpoints and further cost-effectiveness analyses.
The firm will use the $19 million it raised in Series A financing to finish developing its platform that can help decentralize CAR T-cell therapy.
The trial will include patients with MTAP-deleted pancreatic or MTAP-deleted RAS-mutant non-small cell lung cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results